Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25508664 | 0.91 | TSHR (0.30) | — | |
| SCHEMBL22737182 | 0.88 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL26743361 | 0.85 | — | — | |
| SCHEMBL24197174 | 0.85 | — | — | |
| SCHEMBL24197192 | 0.85 | — | — | |
| SCHEMBL24185483 | 0.85 | TSHR (0.33) | CYP1A2 | |
| SCHEMBL25508639 | 0.82 | OPRL1 (0.32) | — | |
| SCHEMBL25814798 | 0.79 | CYP1A2 (0.33) | CYP1A2 | |
| SCHEMBL21478291 | 0.79 | — | — | |
| SCHEMBL25466759 | 0.79 | OPRM1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | XIZANG HAISCO PHARMACEUTICALS CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| WO-2023131167-A1 | COMPOUND FOR INHIBITING AND DEGRADING IRAK4, AND PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 海思科医药集团股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| EP-4180427-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357193-A1 | COMPOUND CAPABLE OF INHIBITING AND DEGRADING ANDROGEN RECEPTORS, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL USES THEREOF | AR, CYP17A1, KLK3 | CYP1A2 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.